Clario, a provider of endpoint data solutions to the clinical trial industry, announced on Monday that it has signed a definitive agreement to acquire the electronic clinical outcomes assessments (eCOA) business of WCG, a company that provides solutions designed to improve and accelerate clinical research.

eCOAs are used in addition to paper assessments to evaluate the safety and efficacy of new drugs by evaluating how a clinical trial participant feels or functions.

WCG's eCOA operations provide full-service clinical expertise and specialised functionality, mainly in neurology, psychiatry, neuropathic pain and rare diseases.

The acquisition is subject to regulatory approvals and other customary closing conditions. Until the transaction closes, both organisations will continue to operate as independent entities.